Philip Friedlander
Impact in
- Oncology top 1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Dermatology top 0.5%
Papers in
- Oncology 49
- Cancer Immunotherapy and Biomarkers 21
- CAR-T cell therapy research 16
- Cancer-related Molecular Pathways 6
- PARP inhibition in cancer therapy 6
-
- Melanoma and MAPK Pathways 11
- vaccines and immunoinformatics approaches 7
- Cancer therapeutics and mechanisms 5
- Co-authors
- Carol Prives (4 shared papers)Axel Hauschild (8 shared papers)Ellen S. Marmur (3 shared papers)Karl D. Lewis (3 shared papers)Sarah T. Arron (3 shared papers)James Solomon (3 shared papers)Simon Yoo (3 shared papers)Michael R. Migden (3 shared papers)
- Journals
- Journal of Clinical Oncology (17 papers)Cancer Research (4 papers)Journal for ImmunoTherapy of Cancer (4 papers)European Journal of Cancer (3 papers)Melanoma Research (3 papers)
- Partner nations
- United StatesGermanyBelgium
In The Last Decade
Philip Friedlander
63 papers receiving 3.9k citations
Philip Friedlander's Hit Papers
Peers
Comparison fields: 5 of 114
- Oncology 2.0k
- Dermatology 469
- Immunology 664
- Molecular Biology 2.2k
- Biotechnology 210
Countries citing papers authored by Philip Friedlander
This map shows the geographic impact of Philip Friedlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Friedlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Friedlander more than expected).
Fields of papers citing papers by Philip Friedlander
This network shows the impact of papers produced by Philip Friedlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Friedlander. The network helps show where Philip Friedlander may publish in the future.
Co-authors
The 25 scholars most cited alongside Philip Friedlander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma Hit paper breakdown → | 2012 | 1074 |
| 2 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 502 |
| 3 | 2008 | 318 | |
| 4 | 1996 | 252 | |
| 5 | 2013 | 249 | |
| 6 | 2005 | 246 | |
| 7 | 2015 | 158 | |
| 8 | 2002 | 120 | |
| 9 | 2018 | 104 | |
| 10 | 1996 | 91 | |
| 11 | 2013 | 77 | |
| 12 | 2004 | 74 | |
| 13 | 2015 | 74 | |
| 14 | 2023 | 64 | |
| 15 | 2013 | 58 | |
| 16 | 2014 | 57 | |
| 17 | 2012 | 45 | |
| 18 | 2011 | 42 | |
| 19 | 2021 | 40 | |
| 20 | 2018 | 38 |
About Philip Friedlander
Philip Friedlander is a scholar working on Oncology, Molecular Biology, Immunology, Biotechnology and Epidemiology, having authored 68 papers that have together received 4.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (17 papers), CAR-T cell therapy research (16 papers), Melanoma and MAPK Pathways (11 papers), vaccines and immunoinformatics approaches (7 papers), Cancer-related Molecular Pathways (6 papers), PARP inhibition in cancer therapy (6 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Oncology (2.0k citations), Dermatology (469 citations), Immunology (664 citations), Molecular Biology (2.2k citations) and Biotechnology (210 citations). Philip Friedlander has collaborated with scholars based in United States, Germany and Belgium. Frequent co-authors include Carol Prives, Axel Hauschild, Ellen S. Marmur, Karl D. Lewis, Sarah T. Arron, James Solomon, Simon Yoo, Michael R. Migden, Luc Dirix and Charles M. Rudin. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Journal for ImmunoTherapy of Cancer, European Journal of Cancer and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.